tenofovir alafenamide

This page shows the latest tenofovir alafenamide news and features for those working in and with pharma, biotech and healthcare.

MSD claims EU approval for two HIV products

In the US, Merck has priced Delstrigo at $70 per day, at the low end of rivals such as Gilead’s Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and ViiV’s Triumeq ... Merck has suggested Delstrigo is slightly more effective than

Latest news

GSK’s says depot HIV injection works over three years

drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
Janssen’s single tablet Symtuza gains NHS England funding

Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]).is once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV-1 infection in adults and adolescents aged ... Biktarvy is a combination of integrase
ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy
GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
Gilead’s Biktarvy gets European approval, setting up battle with GSK

The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

More from news
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Senior Medical Writer: Great salary and benefits

Digital Account Director: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director, Medical Education: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...